| Full Name | Kathy Clemens |
|---|---|
| Gender | Female |
| Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
| Location | 7 3rd St, Bristol, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194316851 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Kathy Clemens, 7 3rd St, Bristol, RI 02809-3225 Ph: (401) 447-4354 | Kathy Clemens, 7 3rd St, Bristol, RI 02809-3225 Ph: (401) 447-4354 |
News Archive
One in every 500 babies is born with a condition called ureteropelvic junction obstruction (UPJO), an obstruction of the ureter that prevents urine from flowing from one or both of the kidneys into the bladder.
Insulin-like growth factor I, IGF-I, is a hormone that is found in the blood and contributes to, among other things, growth and bone mass. The levels of this hormone are higher in people who exercise regularly and those with good health. Scientists at the Sahlgrenska Academy have shown for the first time that high levels of this hormone are associated with better long-term recovery after a stroke.
Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA's Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar's efficacy and safety in the proposed patient population.
The National Institutes of Health has awarded University of Miami researchers $14 million for an ambitious seven-year project that will keep the Miller School of Medicine at the forefront of cutting-edge HIV research.
BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.
› Verified 9 days ago
Dr. Alyssa Emily Capuano, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2 Betsy Dr, Bristol, RI 02809 Phone: 401-525-6202 | |
Kenneth Olszewski, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 Metacom Ave, Bristol, RI 02809 Phone: 401-253-2050 | |
Rachel Elise Borges, B.S. PHARMD RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 591 Metacom Ave, Bristol, RI 02809 Phone: 401-254-3903 | |
Elsiris Rosario, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 591 Metacom Ave, Bristol, RI 02809 Phone: 401-254-3903 Fax: 401-254-3907 | |
Bethany Barone, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 Metacom Ave, Bristol, RI 02809 Phone: 401-253-2050 | |
Susan Helen Levesque-degrazia, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 Metacom Ave, Bristol, RI 02809 Phone: 401-253-2050 Fax: 401-254-7413 |